Kamada Ltd. (NASDAQ:KMDA - Free Report) - HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Kamada in a research note issued to investors on Thursday, August 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.47 for the year, up from their previous forecast of $0.39. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's Q4 2025 earnings at $0.17 EPS, FY2026 earnings at $0.50 EPS, FY2027 earnings at $0.71 EPS and FY2028 earnings at $0.78 EPS.
Kamada (NASDAQ:KMDA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The business had revenue of $44.75 million during the quarter, compared to analysts' expectations of $158.59 million. Kamada had a return on equity of 7.41% and a net margin of 11.22%. Kamada has set its FY 2025 guidance at EPS.
Several other brokerages have also recently commented on KMDA. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Benchmark reaffirmed a "buy" rating and issued a $15.00 target price on shares of Kamada in a research report on Thursday, May 15th. Finally, Sidoti raised Kamada to a "hold" rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.00.
Read Our Latest Research Report on KMDA
Kamada Stock Down 3.7%
Shares of Kamada stock traded down $0.27 during midday trading on Friday, hitting $6.97. The company's stock had a trading volume of 94,971 shares, compared to its average volume of 132,785. The firm has a market capitalization of $400.84 million, a P/E ratio of 20.50, a PEG ratio of 0.76 and a beta of 0.93. The stock has a 50-day simple moving average of $7.47 and a 200-day simple moving average of $7.07. Kamada has a 1-year low of $5.17 and a 1-year high of $9.15.
Institutional Trading of Kamada
Hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its holdings in Kamada by 3.1% during the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company's stock valued at $2,053,000 after buying an additional 7,925 shares in the last quarter. ARK Investment Management LLC bought a new position in Kamada during the second quarter valued at about $1,972,000. Huntleigh Advisors Inc. raised its holdings in Kamada by 3.9% during the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company's stock valued at $1,052,000 after buying an additional 5,151 shares in the last quarter. Jane Street Group LLC bought a new position in Kamada during the first quarter valued at about $582,000. Finally, Goldman Sachs Group Inc. bought a new position in Kamada during the first quarter valued at about $497,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
